AUTHOR=Zheng Yang , Zou Jiayu , Sun Chen , Peng Fu , Peng Cheng TITLE=Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers JOURNAL=Frontiers in Molecular Biosciences VOLUME=10 YEAR=2023 URL=https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1165781 DOI=10.3389/fmolb.2023.1165781 ISSN=2296-889X ABSTRACT=
Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. However, HER2 overexpression and gene amplification have also been reported in other cancers like gastric cancer, non-small cell lung cancer (NSCLC), and colorectal cancer